Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2001, p. 2147-2150, Vol. 45, No. 7
Department of Medical Microbiology, Faculty
of Medicine1 and Faculty of
Pharmacy,3 University of Manitoba, and
Departments of Medicine4 and Clinical
Microbiology,2 Health Sciences Centre, Winnipeg,
Manitoba, Canada
Received 22 January 2001/Returned for modification 2 March
2001/Accepted 9 April 2001
In this study (1998-1999), we collected 215 macrolide-resistant
Streptococcus pneumoniae isolates from an ongoing Canadian Respiratory Organism Surveillance Study involving 23 centers
representing all regions of Canada. The prevalence of
erythromycin-resistant S. pneumoniae was 8% (215 of
2,688). Of the 215 isolates, 48.8% (105 of 215) were PCR positive for
mef(A) and 46.5% (100 of 215) were PCR positive for
erm(B). The ketolides telithromycin and ABT-773
demonstrated excellent activity against both mef(A) (MIC for 90% of strains [MIC90], 0.06 and 0.03 µg/ml,
respectively) and erm(B) (MIC90, 0.06 and 0.03 µg/ml, respectively) strains of S. pneumoniae.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2147-2150.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Macrolide-Resistant Streptococcus
pneumoniae in Canada during 1998-1999: Prevalence of
mef(A) and erm(B) and Susceptibilities to
Ketolides
*
Corresponding author. Mailing address: Department of
Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook
Street, Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-4902. Fax: (204) 787-4699. E-mail: ggzhanel{at}pcs.mb.ca.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |